Device Trial Radar · NCT07087353
Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
594
Planned (sponsor's estimate)
Start
Oct 31, 2025
Primary completion
Jun 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- ResilienceNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 28, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Mood disorders like depression and bipolar disorder are widespread and cause serious psychological, cognitive, and social impairments, with a high burden on healthcare systems. Edra PRO is a digital medical device developed to support clinical decision-making and remotely monitor symptoms in psychiatric patients. The EC-102 randomized controlled trial will evaluate its impact compared to usual care on symptoms, quality of life, healthcare costs, comorbidities, and user adherence and satisfaction.
Conditions
- Mood Disorder (Depressive Episodes)
Interventions
Edra PRODevice
Remote monitoring software
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate over a 6-month period.Time frame: Month 6
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
CHU Besançon
Besançon, France · Recruiting
CHU Grenoble Alpes
Grenoble, France · Recruiting
EPSM de VEndée
La Roche-sur-Yon, France · Recruiting
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.